Related Experiment Video
Updated: Oct 7, 2025
Antigen-Capture Enzyme-Linked Immunosorbent Assay for Specific Detection of Mycoplasma pneumoniae
Published on: February 24, 2023
An immunoinformatics-based designed multi-epitope candidate vaccine (mpme-VAC/STV-1) against Mycoplasma pneumoniae
Thaís Cristina Vilela Rodrigues1, Arun Kumar Jaiswal1, Marcela Rezende Lemes2
1Programa PG Em Bioinformática, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
Abstract:
Pneumonia is a serious global health problem that accounts for over one million deaths annually. Among the main microorganisms causing pneumonia, Mycoplasma pneumoniae is one of the most common ones for which a vaccine is immediately required. In this context, a multi-epitope vaccine against this pathogen could be the best option that can induce effective immune response avoiding any serious adverse reactions. In this study, using an immunoinformatics approach we have designed a multi-epitope vaccine (mpme-VAC/STV-1) against M. pneumoniae. Our designed mpme-VAC/STV-1 is constructed using CTL (cytotoxic T lymphocyte), HTL (Helper T lymphocyte), and B-cell epitopes. These epitopes are selected from the core proteins of 88 M. pneumoniae genomes that were previously identified through reverse vaccinology approaches. The epitopes were filtered according to their immunogenicity, population coverage, and several other criteria. Sixteen CTL/B- and thirteen HTL/B- epitopes that belong to 5 core proteins were combined together through peptide linkers to develop the mpme-VAC/STV-1. The heat-labile enterotoxin from E. coli was used as an adjuvant. The designed mpme-VAC/STV-1 is predicted to be stable, non-toxic, non-allergenic, non-host homologous, and with required antigenic and immunogenic properties. Docking and molecular dynamic simulation of mpme-VAC/STV-1 shows that it can stimulate TLR2 pathway mediated immunogenic reactions. In silico cloning of mpme-VAC/STV-1 in an expression vector also shows positive results. Finally, the mpme-VAC/STV-1 also shows promising efficacy in immune simulation tests. Therefore, our constructed mpme-VAC/STV-1 could be a safe and effective multi-epitope vaccine for immunization against pneumonia. However, it requires further experimental and clinical validations.
Insights
A novel multi-epitope vaccine (mpme-VAC/STV-1) was designed using immunoinformatics to combat Mycoplasma pneumoniae, a common cause of pneumonia. This potential vaccine shows promise for safe and effective immunization against pneumonia.
Area of Science:
- Vaccinology
- Immunoinformatics
- Computational Biology
Background:
- Pneumonia causes over a million deaths annually, with Mycoplasma pneumoniae being a key pathogen requiring vaccine development.
- Multi-epitope vaccines offer a promising strategy for effective immune response with reduced adverse reactions.
Purpose of the Study:
- To design a multi-epitope vaccine (mpme-VAC/STV-1) against Mycoplasma pneumoniae using an immunoinformatics approach.
- To evaluate the potential efficacy, safety, and immunogenic properties of the designed vaccine candidate.
Main Methods:
- Utilized immunoinformatics and reverse vaccinology to identify and select cytotoxic T lymphocyte (CTL), Helper T lymphocyte (HTL), and B-cell epitopes from 88 M. pneumoniae genomes.
- Constructed the multi-epitope vaccine by combining selected epitopes with peptide linkers and incorporating an adjuvant (heat-labile enterotoxin from E. coli).
- Assessed vaccine properties through in silico analyses including stability, toxicity, allergenicity, host homology, antigenicity, immunogenicity, molecular docking, dynamic simulations, and immune simulations.
Main Results:
- The designed mpme-VAC/STV-1 is predicted to be stable, non-toxic, non-allergenic, and non-host homologous, possessing desirable antigenic and immunogenic characteristics.
- Molecular simulations indicate that mpme-VAC/STV-1 can elicit immunogenic reactions via the TLR2 pathway.
- In silico cloning and immune simulation tests demonstrated positive results, suggesting promising efficacy.
Conclusions:
- The in silico designed mpme-VAC/STV-1 represents a potential safe and effective multi-epitope vaccine candidate against Mycoplasma pneumoniae.
- Further experimental validation and clinical trials are necessary to confirm the efficacy and safety of this vaccine for immunization against pneumonia.
